瑞舒伐他汀联合依折麦布治疗急性心肌梗死患者的临床效果观察  

Clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction

作　　者：张艳芳 王彦雯 ZHANG Yan-fang;WANG Yan-wen(People's Hospital of Inner Mongolia Autonomous Region,Hohhot 010010,China)

机构地区：[1]内蒙古自治区人民医院,010010

出　　处：《中国实用医药》2022年第17期101-103,共3页China Practical Medicine

摘　　要：目的 探讨瑞舒伐他汀联合依折麦布治疗急性心肌梗死(AMI)的临床疗效。方法 92例AMI患者,随机分为对照组和观察组,每组46例。对照组采取瑞舒伐他汀治疗,观察组在对照组基础上联合依折麦布治疗。比较两组临床疗效、不良事件发生率及治疗前后血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]水平。结果 随访过程中有2例患者因肝功异常停止研究观察,其中对照组和观察组各1例。观察组总有效率为95.56%,高于对照组的80.00%,差异有统计学意义(P<0.05);观察组不良事件发生率为13.33%,低于对照组的35.56%,差异有统计学意义(P<0.05)。治疗后,两组TC、TG、LDL-C水平均低于本组治疗前, HDL-C水平高于本组治疗前,且观察组TC(3.58±0.68)mmol/L、TG(2.03±0.54)mmol/L、LDL-C(1.65±0.44)mmol/L均低于对照组的(4.35±0.83)、(2.42±0.65)、(2.56±0.61)mmol/L, HDL-C(1.93±0.41)mmol/L高于对照组的(1.58±0.31)mmol/L,差异具有统计学意义(P<0.05)。结论 瑞舒伐他汀联合依折麦布治疗AMI临床疗效显著,可有效改善机体血脂水平,降低不良事件发生率,值得推广。Objective To discuss the clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction(AMI).Methods A total of 92 cases of AMI patients were randomly divided into control group and observation group,with 46 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with ezetimibe on the basis of the control group.Both groups were compared in terms of clinical efficacy,incidence of adverse events,and blood lipid indexes[triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol(HDL-C)]before and after treatment.Results During the follow-up,2 patients stopped the study and observation due to abnormal liver function,including 1 case each in the observation group and the control group.The total effective rate in the observation group was 95.56%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse events in the observation group was 13.33%,which was lower than 35.56%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of TC,TG and LDL-C in the two groups were lower than those before treatment in this group,and the HDL-C was higher than that before treatment in this group;the TC(3.58±0.68)mmol/L,TG(2.03±0.54)mmol/L,and LDL-C(1.65±0.44)mmol/L in the observation group were lower than(4.35±0.83),(2.42±0.65),(2.56±0.61)mmol/L in the control group,and the HDL-C(1.93±0.41)mmol/L was higher than(1.58±0.31)mmol/L in the control group.All the differences were statistically significant(P<0.05).Conclusion Rosuvastatin combined with ezetimibe has significant clinical efficacy in the treatment of AMI,and can effectively improve the blood lipid and reduce the incidence of adverse events,which is worthy of promotion.

关 键 词：瑞舒伐他汀 依折麦布 急性心肌梗死 血脂 不良事件 

分 类 号：R542.22[医药卫生—心血管疾病]